Addressing Concerns for Neoadjuvant Therapies in Locally Advanced Kidney Cancer
Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.
Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.
One of the biggest concerns with neoadjuvant approaches compared with adjuvant treatments for nonmetastatic disease is whether neoadjuvant therapies will delay the timing of surgeries, according to Voss. Most of the drugs used in the neoadjuvant setting have proven to work well with subsequent surgery and have not postponed timing.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
